Novel Targeted Treatment Offers Potential Option for Men With Advanced Prostate Cancer

A novel therapy using 2 targeted treatments shows promise for men with advanced prostate cancer, according to research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Although there have been great treatment advances, metastatic castrate resistant prostate cancer (mCRPC) remains a deadly disease. Trials with the targeted radionuclide therapy 177Lu PSMA 617 have proven safe and effective in some men; however, not all respond to treatment, and responses may be limited in duration.

To build upon these trials, researchers paired 177Lu PSMA 617 with the tumour-specific radiation sensitizer idronoxil (NOX66) to assess responses in heavily treated patients with mCRPC.

The phase 1/2 study enrolled 16 men with progressing mCRPC, despite previous treatments. All men received up to 6 doses of 177Lu PSMA 617 at 6-week intervals. Half the patients (cohort 1) received additional treatment with NOX66 400 mg/day for 10 days. Following a safety data review, the remaining patients (cohort 2) received additional treatment with NOX66 800 mg/day.

Results showed that nearly 70% of all patients saw a more than 50 percent reduction in prostate-specific antigen (PSA) levels (62.5% in cohort 1 and 75% in cohort 2) after the combination treatment. Adverse side effects, such as fatigue and pneumonitis, were reported in 37.5% and 12.5%, respectively.

“The initial results of this phase 1 dose escalation study show that the combination targeted treatments were well tolerated, with no increase in toxicity from 177Lu PSMA 617, and an apparent high efficacy in men who have already had extensive treatments,” said Louise Emmett, MD, University of New South Wales, Sydney, Australia.

“We are now in a dose expansion phase 2 stage to further evaluate toxicity and efficacy,” she added. “This raises the very important possibilities of combining tumour-targeted therapeutic agents to gain synergistic treatment effects without an increase in side effects.”


SOURCE: Society of Nuclear Medicine and Molecular Imaging
Log in to post comments

Tell us what you think of DG News

Click to like Click to dislike